These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 19356120)

  • 1. New frontiers in the therapy of tuberculosis: fighting with the global menace.
    Chhabria M; Jani M; Patel S
    Mini Rev Med Chem; 2009 Apr; 9(4):401-30. PubMed ID: 19356120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting tuberculosis: a glimpse of promising drug targets.
    Arora N; Banerjee AK
    Mini Rev Med Chem; 2012 Mar; 12(3):187-201. PubMed ID: 22356190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New tuberculosis drugs on the horizon.
    Cole ST; Riccardi G
    Curr Opin Microbiol; 2011 Oct; 14(5):570-6. PubMed ID: 21821466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Harnessing Biological Insight to Accelerate Tuberculosis Drug Discovery.
    de Wet TJ; Warner DF; Mizrahi V
    Acc Chem Res; 2019 Aug; 52(8):2340-2348. PubMed ID: 31361123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in the research of heterocyclic compounds as antitubercular agents.
    Yan M; Ma S
    ChemMedChem; 2012 Dec; 7(12):2063-75. PubMed ID: 23042656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Recent progress in mycobacteriology].
    Okada M; Kobayashi K
    Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
    Tomioka H
    Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Importance of differential identification of Mycobacterium tuberculosis strains for understanding differences in their prevalence, treatment efficacy, and vaccine development.
    Chae H; Shin SJ
    J Microbiol; 2018 May; 56(5):300-311. PubMed ID: 29721826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prospects for development of new antituberculous drugs].
    Tomioka H
    Kekkaku; 2002 Aug; 77(8):573-84. PubMed ID: 12235850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isoniazid derivatives and their anti-tubercular activity.
    Hu YQ; Zhang S; Zhao F; Gao C; Feng LS; Lv ZS; Xu Z; Wu X
    Eur J Med Chem; 2017 Jun; 133():255-267. PubMed ID: 28390957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug targets exploited in Mycobacterium tuberculosis: Pitfalls and promises on the horizon.
    Bhat ZS; Rather MA; Maqbool M; Ahmad Z
    Biomed Pharmacother; 2018 Jul; 103():1733-1747. PubMed ID: 29864964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SAR analysis of new anti-TB drugs currently in pre-clinical and clinical development.
    Poce G; Cocozza M; Consalvi S; Biava M
    Eur J Med Chem; 2014 Oct; 86():335-51. PubMed ID: 25173852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The resumption of consumption -- a review on tuberculosis.
    Ducati RG; Ruffino-Netto A; Basso LA; Santos DS
    Mem Inst Oswaldo Cruz; 2006 Nov; 101(7):697-714. PubMed ID: 17160276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Frontier of mycobacterium research--host vs. mycobacterium].
    Okada M; Shirakawa T
    Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trends in the discovery of new drugs for Mycobacterium tuberculosis therapy with a glance at resistance.
    Lohrasbi V; Talebi M; Bialvaei AZ; Fattorini L; Drancourt M; Heidary M; Darban-Sarokhalil D
    Tuberculosis (Edinb); 2018 Mar; 109():17-27. PubMed ID: 29559117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New structural classes of antituberculosis agents.
    Kumar V; Patel S; Jain R
    Med Res Rev; 2018 Mar; 38(2):684-740. PubMed ID: 28598559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging therapeutic targets in tuberculosis: post-genomic era.
    Khasnobis S; Escuyer VE; Chatterjee D
    Expert Opin Ther Targets; 2002 Feb; 6(1):21-40. PubMed ID: 11901479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current Advances in Antitubercular Drug Discovery: Potent Prototypes and New Targets.
    Dos Santos Fernandes GF; Jornada DH; de Souza PC; Chin CM; Pavan FR; Dos Santos JL
    Curr Med Chem; 2015; 22(27):3133-61. PubMed ID: 26282941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving the tuberculosis drug development pipeline.
    Evangelopoulos D; McHugh TD
    Chem Biol Drug Des; 2015 Nov; 86(5):951-60. PubMed ID: 25772393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.